Platelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000 cells/uL (75 x 10^9 L); and,Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ul (within 14 days of treatment initiation)Xx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets ? 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 K/uLXx_NEWLINE_xXObtained within 14 days prior to C1D1: Platelets >= 100,000 4/uLXx_NEWLINE_xXPlatelets 100,000/ul or moreXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 K/uLXx_NEWLINE_xXPlatelets >= 100 K/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 K/uLXx_NEWLINE_xXPlatelets ? 100,000/uL within 28 days prior to registrationXx_NEWLINE_xXPlatelets ? 60 K/uLXx_NEWLINE_xXWithin 14 days prior to registration: Platelets >= 100,000/uLXx_NEWLINE_xXPlatelets (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000 cells/ulXx_NEWLINE_xXPlatelets >= 100,000 cells/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXThrombocytopenia (platelets [Plt] < 100,000/ul)Xx_NEWLINE_xXPlatelets >= 100,000/uL within 14 days prior to first dose of protocol-indicated treatment.Xx_NEWLINE_xXWithin 14 days of the first dose of study drug: Platelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets > 70,000/uLXx_NEWLINE_xXWithin 10 days prior to the start of study treatment: Platelets >= 100 000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uL.Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets ? 20,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100 k/uLXx_NEWLINE_xXObtained within 14 days prior to randomization/registration: platelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets ? 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets 100,000/ul or moreXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets 100,000/ul or moreXx_NEWLINE_xXPlatelets >= 100,000/ul.Xx_NEWLINE_xXPlatelets >= 60,000/Ul.Xx_NEWLINE_xXPlatelets >= 100 K/ULXx_NEWLINE_xXSubjects with neutrophils < 1500/uL or platelets < 100,000/uL with splenomegaly or extensive bone marrow involvement as the etiology for their cytopenias are eligibleXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ul (unsupported)Xx_NEWLINE_xXPlatelets >= 125,000 cells/ul (prior to biopsy)Xx_NEWLINE_xXPlatelets >= 100,000/uL.Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXWithin 28 days prior to enrollment: Platelets >= 100,000/uLXx_NEWLINE_xXObtained within 21 days prior to randomization/registration: Platelets >= 100 x 10^3/uL.Xx_NEWLINE_xXNo more than 14 days prior to registration: Platelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 150,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ uL, within 2 weeks of registration (except where specified otherwise)Xx_NEWLINE_xXPlatelets (PLT) >= 100 x 10^3/uL, within 30 days before study registrationXx_NEWLINE_xXPlatelets >= 100,000 /uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets =< 100,000/uLXx_NEWLINE_xXPlatelets >= 100x10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uL obtained < 4 weeks prior to starting treatmentXx_NEWLINE_xXObtained within 14 days of randomization: Platelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelet count >= 125,000/uL prior to biopsy; platelets >= 100,000/uL prior to infusionXx_NEWLINE_xXPlatelets >= 100 X 10^3/uLXx_NEWLINE_xXPlatelets < 100,000 cells/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uL within 14 days prior to study entryXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uL (performed within 28 days of registration)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3 /uLXx_NEWLINE_xXPlatelets > 70,000/uLXx_NEWLINE_xXPlatelets >= 100,00/uLXx_NEWLINE_xXPlatelets >= 100,000 per uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets < 20,000/ul prior to treatmentXx_NEWLINE_xXPlatelets >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days\r\nprior to laboratory sample)Xx_NEWLINE_xXPlatelets >= to 100,000 /uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000 platelets/ulXx_NEWLINE_xXPlatelets >= 100,000/ul, (75,000/ul if due to bone marrow [BM] involvement)Xx_NEWLINE_xXPlatelets >= 100,000/uL obtained within 14 days of first treatmentXx_NEWLINE_xXPlatelets >= 100 x10^3/uL obtained within 14 days prior to randomization/registrationXx_NEWLINE_xXPlatelets >= 100,000 cells/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets greater than or equal to 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/ul (transfusion independent)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets (Plts) >= 100,000 /uLXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uL (without transfusion or growth factor support), performed within 28 days prior to registrationXx_NEWLINE_xXPlatelets >= 100,000/uL within 14 days of the first dose of study drugXx_NEWLINE_xXPlatelets >= 100,000/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapyXx_NEWLINE_xXPlatelets > 100,000 cells/ulXx_NEWLINE_xXPlatelets >= 100,000 cells/uL (to be performed within 7 days prior to start of study treatment)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000 cells/ulXx_NEWLINE_xXLeukocyte >= 3,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets > 100,000/ul (transfusion independent)Xx_NEWLINE_xXSubjects with neutrophils < 1500/uL or platelets < 100,000/uL with splenomegaly or extensive bone marrow involvement as the etiology for their cytopenias are eligibleXx_NEWLINE_xXPlatelets >= 120,000/uLXx_NEWLINE_xXPlatelets (PLT) >= 100,000 uLXx_NEWLINE_xXPlatelets >= 100,000 /uLXx_NEWLINE_xXPlatelets >= 100,000 per uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uL (non-transfused)Xx_NEWLINE_xXPlatelets > 100,000/ul (transfusion independent)Xx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets >= 70,000 /uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelet count >/= 100,000 platelets/ul prior to initial treatmentXx_NEWLINE_xXPlatelets (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Platelets >= 100,000/uL (mcL)Xx_NEWLINE_xXTREATMENT: Platelets >= 100,000/uL (mcL)Xx_NEWLINE_xXPlatelets >= 100 x10^3/uLXx_NEWLINE_xXPlatelets 100,000/ul or moreXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXSecondary Registration: platelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uL (untransfused)Xx_NEWLINE_xXPlatelets (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 000/uL, specimens must be collected within 10 days prior to the start of study treatmentXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 90 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXWithin 14 days of subject registration: Platelets 100,000/uL (no transfusion allowed within 2 weeks)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXHematologic criteria: ANC <  500/uL, Platelets < 25,000 uL.Xx_NEWLINE_xXPlatelets (PLT) >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 50k/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXThrombocytopenia (platelets [Plt] < 100,000/ul)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ul (no platelet transfusion allowed within 2 weeks)Xx_NEWLINE_xXPerformed within 14 days of patient registration: Platelets >= 100,000/uL (no transfusion allowed within 2 weeks)Xx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets greater than or equal to 100 K/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets >= 160,000/ulXx_NEWLINE_xXPlatelets ?100,000/uL (microliter)Xx_NEWLINE_xXPlatelets ? 30 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >=100,000/uL.Xx_NEWLINE_xXPlatelets: >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 50000/uLXx_NEWLINE_xXPlatelets >= 100,000 /uLXx_NEWLINE_xXPlatelets >= 100,000/ul (untransfused)Xx_NEWLINE_xXPlatelets >= 100,000/uL obtained =< 7 days prior to randomizationXx_NEWLINE_xXPlatelets > 100 x10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXWithin 4 weeks of administration of study therapy: Platelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 125,000 cells/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100 × 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/ul (unless these abnormalities are due to bone marrow involvement)Xx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ul (unsupported)Xx_NEWLINE_xXPlatelets (PLT) >= 100,000 / uLXx_NEWLINE_xXPlatelets >= 90 x 10^3/uLXx_NEWLINE_xXPlatelets (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ul (no transfusion allowed within 2 weeks)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100 K/ULXx_NEWLINE_xXPlatelets >= 100,000 per uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets < 100,000 /uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/UlXx_NEWLINE_xXPlatelets > 100,000/uL prior to day 0Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets greater than or equal to 100,000/ul, CTCAE grade 0-1Xx_NEWLINE_xXWithin 14 days after subjects signed the treatment consent: Platelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 125,000/ul prior to biopsy; platelets >= 100,000/ul prior to infusionXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uL, within 14 days of registrationXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 30,000/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXWithin 14 days prior to enrollment/randomization: Platelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000 cells/ulXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ul (unless low platelets are due to multiple myeloma)Xx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets > 100 x 10^9/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets greater than or equal to 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000//uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXNeutrophils >= 1,000/ulXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXALC >100/uLXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 100,000 /uL without transfusion within 10 days prior to doseXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ul; low platelet counts may be corrected with transfusion to achieve eligibility for studyXx_NEWLINE_xXPlatelets >= 50000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >=100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXThrombocytopenia (<30,000/uL)Xx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets > 100 K/uLXx_NEWLINE_xXPlatelets > 100 K/uLXx_NEWLINE_xXPlatelets greater than or equal to 100,000/ul (CTCAE grade 0-1)Xx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uLXx_NEWLINE_xXPlatelets >= 30,000/ulXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets >= 150,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPatients with platelets >= 100,000/uL (without platelets transfusion for at least one week prior to blood test date); the most recent platelets level taken within 60 days prior to study enrollment will be consideredXx_NEWLINE_xXPlatelets > 100,000 cells/ulXx_NEWLINE_xXPlatelets >= 100 x 10^3/uL, obtained within 14 days of the first dose of study drugXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000 cells/uLXx_NEWLINE_xXPlatelets > 100,000/uLXx_NEWLINE_xXPlatelets >= 100,000/uLXx_NEWLINE_xXPlatelets > 100,000/ulXx_NEWLINE_xXPlatelets ? 30,000/uLXx_NEWLINE_xXThrombocytopenia (platelets < 100,000 cells/uL)Xx_NEWLINE_xX